Literature DB >> 21850425

Pregabalin: a treatment option for dystonia?

Christina Karosin1, Markus Kofler, Andreas Mayr, Leopold Saltuari.   

Abstract

To date, no studies are available on the effect of pregabalin in dystonia. A patient with subarachnoidal and cerebral hemorrhage was treated with pregabalin for neuropathic pain. Upon withdrawal of the medication she experienced spontaneous and painful supination in the right foot and internal hip rotation when standing up. When pregabalin was reinstituted, these dystonic symptoms subsided, but reappeared when the medication was again discontinued. One possible explanation for these symptoms could be neuronal hyperactivity within still-functioning pathways in connection with the motor cortex. Preponderance of activity in potentially compensatory structures could be suppressed by pregabalin: therefore, its potential benefit in subacute secondary dystonia in cases with orbital brain involvement is suggested.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21850425     DOI: 10.1007/s10072-011-0737-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  15 in total

Review 1.  The mechanisms of action of gabapentin and pregabalin.

Authors:  Graeme J Sills
Journal:  Curr Opin Pharmacol       Date:  2005-12-22       Impact factor: 5.547

2.  Preserved motor evoked potentials fail to predict functional outcome in quadriplegia because of bilateral lesions of the supplementary motor areas: a brief report.

Authors:  M Kofler; N Morota; V Deletis
Journal:  Am J Phys Med Rehabil       Date:  1999 Jan-Feb       Impact factor: 2.159

3.  Gabapentin for familial paroxysmal dystonic choreoathetosis.

Authors:  R S Chudnow; R A Mimbela; D B Owen; E S Roach
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

4.  Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.

Authors:  A Serrano; J Menéndez; M J Casarejos; R M Solano; E Gallego; M Sánchez; M A Mena; J García de Yebenes
Journal:  Neuropharmacology       Date:  2005-08       Impact factor: 5.250

5.  EFNS guidelines on diagnosis and treatment of primary dystonias.

Authors:  A Albanese; F Asmus; K P Bhatia; A E Elia; B Elibol; G Filippini; T Gasser; J K Krauss; N Nardocci; A Newton; J Valls-Solé
Journal:  Eur J Neurol       Date:  2011-01       Impact factor: 6.089

6.  Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice.

Authors:  Indu Joshi; Charles P Taylor
Journal:  Eur J Pharmacol       Date:  2006-09-23       Impact factor: 4.432

Review 7.  Tricyclic antidepressant-induced extrapyramidal side effects.

Authors:  P Vandel; B Bonin; E Leveque; D Sechter; P Bizouard
Journal:  Eur Neuropsychopharmacol       Date:  1997-08       Impact factor: 4.600

8.  Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin.

Authors:  D J Dooley; C M Donovan; T A Pugsley
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

9.  Pregabalin-induced parkinsonism: a case report.

Authors:  Santiago Perez Lloret; Mariela Amaya; Marcelo Merello
Journal:  Clin Neuropharmacol       Date:  2009 Nov-Dec       Impact factor: 1.592

10.  Effects of substance P on neuronal firing of pallidal neurons in parkinsonian rats.

Authors:  Qiao-Ling Cui; Wing-Ho Yung; Lei Chen
Journal:  Neurosci Res       Date:  2007-10-30       Impact factor: 3.304

View more
  1 in total

1.  Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit -A case report-.

Authors:  Youn Yi Jo; Yong Beom Kim; Mi Ran Yang; Young Jin Chang
Journal:  Korean J Anesthesiol       Date:  2012-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.